Skip to main content
"The speed of our forward motion is directly related to the velocity of the people around us."
- Seth Godin
https://t.c

Dr. John Cush RheumNow

2 years 8 months ago
"The speed of our forward motion is directly related to the velocity of the people around us." - Seth Godin https://t.co/9Abzj19Hp9 https://t.co/FxitvtO6sl
Metanalysis (60 RCTs; 20,418 SpA & PsA pts Rx 17 b/tsDMARDs) shows increased NonSerious infections (RR 1.15), @highe

Dr. John Cush RheumNow

2 years 8 months ago
Metanalysis (60 RCTs; 20,418 SpA & PsA pts Rx 17 b/tsDMARDs) shows increased NonSerious infections (RR 1.15), @higher doses, longer Rx; mainly URI & ENT infxn, Signif for axSpA (RR 1.32), not PsA(RR 1.05). SIE were NOT increased https://t.co/Ab9Q9NRFu3 https://t.co/Gzoe3sRaXp
Swedish registry shows #PsA mortality risk ~11% (HR 1.11) higher than general pop., driven by comorbidity, esp in women

Dr. John Cush RheumNow

2 years 8 months ago
Swedish registry shows #PsA mortality risk ~11% (HR 1.11) higher than general pop., driven by comorbidity, esp in women (HR: 1.23) w/ longer Dz duration (HR: 1.18). Causes of death lead by CV Dz and malignancy. https://t.co/M6muM2UIkN https://t.co/az3kig9pBu
The role of thromboprophylaxis following total hip (THA) or total knee arthroplasty (TKA) is uncertain and consensus is lacking. A recent study suggests that thromboprophylaxis strategies should be tailored to individual risk of thrombosis and bleeding.
Race to the top: how high will treatment response rates in RA reach?

We have become used to the 60/40/20% rule for the

Dr. John Cush RheumNow

2 years 8 months ago
Race to the top: how high will treatment response rates in RA reach? We have become used to the 60/40/20% rule for the outcome of ACR 20/50/70 for biologics and targeted synthetic DMARDs. https://t.co/VJplM5GC31 https://t.co/gNsN3wX5tA
2023 EULAR #PMR referral recommendations:
1 Suspected/Dx pts: consider Rheum eval
2 Do full Hx+PE+Labs before referral
3

Dr. John Cush RheumNow

2 years 8 months ago
2023 EULAR #PMR referral recommendations: 1 Suspected/Dx pts: consider Rheum eval 2 Do full Hx+PE+Labs before referral 3 Refer Severe Sx PMR to rapid access 4 Defer steroids til rapid Rheum eval 5 Rheum Dx PMR w? +steroid response can be Rx by PCP https://t.co/42bL8BL3QJ https://t.co/ffpKoKXZJM
Withdraw DMARDS after remission?

Considering withdrawing DMARDs after remission is on our minds. When patients inquire

Dr. John Cush RheumNow

2 years 8 months ago
Withdraw DMARDS after remission? Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer. https://t.co/mQKhwv9wCt https://t.co/Q57t63vNKe
The window of opportunity concept in RA shifted our focus to trying to treat disease earlier and more aggressively to improve long term outcomes. A natural development of this was to reconsider the possibility of therapeutic interventions aimed at the prevention of rheumatoid arthritis.
Promising Therapies for Sjogren's
Adult-onset Still’s disease is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis characterized by sustained fever, salmon-colored rash, and arthritis. The 2023 ACR convergence featured several abstracts spotlighting developments in understanding and managing this complex disease spectrum.
Calcineurin Inhibitors in Lupus Nephritis

Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at t

Dr. John Cush RheumNow

2 years 8 months ago
Calcineurin Inhibitors in Lupus Nephritis Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/4CjJ8Ri3ym https://t.co/KUONVdMfBB
How do we Diversify Clinical Trials?

Dr. Rachel Tate talks with Dr. Irene Blanco at the 2023 ACR Convergence meeting i

Dr. John Cush RheumNow

2 years 8 months ago
How do we Diversify Clinical Trials? Dr. Rachel Tate talks with Dr. Irene Blanco at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/fZ7kKfdRwP https://t.co/Non3X7zOxA
Is MTX Safe in the Elderly?

Dr.Cush reviews this past week's news from RheumNow. Good news is that nearly 99% of adul

Dr. John Cush RheumNow

2 years 8 months ago
Is MTX Safe in the Elderly? Dr.Cush reviews this past week's news from RheumNow. Good news is that nearly 99% of adult rheumatology positions matched! But 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled. https://t.co/un9CbyYooL https://t.co/ilABvgr7bH
×